Reference number	
Study ID (Author Year):	
Data abstractor initials:	

Study citation(s):

SCREENING AND INCLUSION

Title Screening

Potential MDA Study? ☐ Yes ☐ No

Abstract Screening

Potential MDA Study? ☐ Yes ☐ No

Full Article Abstraction

Study inclusion criteria for mass drug administration:

Therapeutic dose of antimalarials given: ☐ Yes ☐ No
Drug given to an entire population or well-defined subpopulation: ☐ Yes ☐ No
Drug administered in a coordinated fashion: ☐ Yes ☐ No
Drug administered without prior diagnostic testing or screening: ☐ Yes ☐ No
Population resides in a malaria endemic area pre and post MDA: ☐ Yes ☐ No

Study inclusion criteria based on study design:

Pre-post measurements done: ☐ Yes ☐ No
Reported estimates of at least one outcome of interest: ☐ Yes ☐ No
Not individually randomized trial: ☐ Yes ☐ No

Study included:

Study meets all inclusion criteria: ☐ Yes ☐ No

If yes, continue with data abstraction
If no, describe reason for exclusion:

Characteristics of excluded studies:

Notes:

Reference number	
Study ID (Author Year):	
Data abstractor initials:	

Study citation(s):

METHODS:

Study location:
Dates of study:
Malaria endemicity:
Main species of malaria:
Main mosquito vectors:
Entomologic inoculation rate:
Study design: (RCT=Randomized controlled trial; Q-RCT=Quasi-randomized controlled trial; NRCT=Non-randomized controlled trial; CBA=Controlled before-and-after study; PCS=Prospective cohort study; RCS=Retrospective cohort study; HCT=Historically controlled trial; NCC=Nested case-control study; CC=Case-control study; XS=Cross-sectional study; BA=Before-and-after comparison; CR/CS=Case report/Case series)
Description of study design:
Study groups:

PARTICIPANTS

Sample size: (specify how many in intervention and how many in control)
Age groups included:

INTERVENTIONS

MDA characteristics: (include regimen, number of times done, timing and coverage)

Co-interventions:

OUTCOMES

Parasitemia prevalence
Gametocytemia prevalence
Parasitemia incidence
Gametocytemia incidence
Clinical illness incidence
Mortality
Anemia
Adverse events

Reference number	
Study ID (Author Year):	
Data abstractor initials:	

RISK OF BIAS (YES, NO, UNCLEAR, N/A, + NOTES FOR EACH SECTION)

Adequate sequence generation	
Appropriate allocation concealment	
Appropriate blinding	
Incomplete outcome data addressed	
Free of selective reporting	
Free of recruitment bias	
Free of baseline imbalance	
No loss of clusters	
Correct analysis	
Free of other bias	
Other specify:	

SUB-GROUP/SENSITIVITY ANALYSIS

High quality study (RCT with low risk of bias by above criteria) (Yes/No)	
Moderate quality study (RCT with moderate to high risk of bias by above criteria or observational study with low risk of bias by above criteria) (Yes/No)	
Early outcome measure after MDA (≤6 months) (Yes/No)	
Late outcome measure after MDA (>6 months) (Yes/No)	
Stand-alone MDA (No co-interventions) (Yes/No)	
Use of chloroquine/primaquine for control of *P. vivax* (Yes/No)	
Other specify:	

NOTES
